![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LARP4B |
Gene summary for LARP4B |
![]() |
Gene information | Species | Human | Gene symbol | LARP4B | Gene ID | 23185 |
Gene name | La ribonucleoprotein 4B | |
Gene Alias | KIAA0217 | |
Cytomap | 10p15.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q92615 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23185 | LARP4B | CCI_1 | Human | Cervix | CC | 7.96e-10 | 9.39e-01 | 0.528 |
23185 | LARP4B | CCI_2 | Human | Cervix | CC | 1.78e-16 | 1.63e+00 | 0.5249 |
23185 | LARP4B | CCI_3 | Human | Cervix | CC | 2.42e-12 | 8.88e-01 | 0.516 |
23185 | LARP4B | HTA11_347_2000001011 | Human | Colorectum | AD | 1.70e-08 | 4.93e-01 | -0.1954 |
23185 | LARP4B | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.18e-06 | 5.32e-01 | 0.281 |
23185 | LARP4B | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.67e-03 | -3.60e-01 | 0.3005 |
23185 | LARP4B | A001-C-207 | Human | Colorectum | FAP | 1.57e-03 | -2.28e-01 | 0.1278 |
23185 | LARP4B | A015-C-203 | Human | Colorectum | FAP | 3.02e-33 | -4.06e-01 | -0.1294 |
23185 | LARP4B | A015-C-204 | Human | Colorectum | FAP | 6.68e-05 | -2.47e-01 | -0.0228 |
23185 | LARP4B | A014-C-040 | Human | Colorectum | FAP | 9.61e-04 | -1.97e-01 | -0.1184 |
23185 | LARP4B | A002-C-201 | Human | Colorectum | FAP | 2.39e-11 | -2.28e-01 | 0.0324 |
23185 | LARP4B | A001-C-119 | Human | Colorectum | FAP | 4.67e-06 | -4.20e-01 | -0.1557 |
23185 | LARP4B | A001-C-108 | Human | Colorectum | FAP | 4.79e-17 | -3.48e-01 | -0.0272 |
23185 | LARP4B | A002-C-205 | Human | Colorectum | FAP | 3.99e-25 | -3.57e-01 | -0.1236 |
23185 | LARP4B | A001-C-104 | Human | Colorectum | FAP | 3.47e-03 | -2.02e-01 | 0.0184 |
23185 | LARP4B | A015-C-006 | Human | Colorectum | FAP | 7.72e-19 | -3.79e-01 | -0.0994 |
23185 | LARP4B | A015-C-106 | Human | Colorectum | FAP | 1.95e-12 | -2.17e-01 | -0.0511 |
23185 | LARP4B | A002-C-114 | Human | Colorectum | FAP | 2.67e-22 | -3.89e-01 | -0.1561 |
23185 | LARP4B | A015-C-104 | Human | Colorectum | FAP | 9.56e-34 | -4.66e-01 | -0.1899 |
23185 | LARP4B | A001-C-014 | Human | Colorectum | FAP | 1.42e-14 | -3.05e-01 | 0.0135 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003133010 | Cervix | CC | negative regulation of cellular catabolic process | 63/2311 | 262/18723 | 1.10e-07 | 5.68e-06 | 63 |
GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 |
GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
GO:000989510 | Cervix | CC | negative regulation of catabolic process | 69/2311 | 320/18723 | 2.15e-06 | 6.55e-05 | 69 |
GO:00064019 | Cervix | CC | RNA catabolic process | 62/2311 | 278/18723 | 2.18e-06 | 6.56e-05 | 62 |
GO:003425010 | Cervix | CC | positive regulation of cellular amide metabolic process | 40/2311 | 162/18723 | 1.11e-05 | 2.41e-04 | 40 |
GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
GO:004572710 | Cervix | CC | positive regulation of translation | 33/2311 | 136/18723 | 9.09e-05 | 1.20e-03 | 33 |
GO:00610139 | Cervix | CC | regulation of mRNA catabolic process | 38/2311 | 166/18723 | 1.07e-04 | 1.36e-03 | 38 |
GO:190331210 | Cervix | CC | negative regulation of mRNA metabolic process | 24/2311 | 92/18723 | 2.49e-04 | 2.77e-03 | 24 |
GO:00467008 | Cervix | CC | heterocycle catabolic process | 80/2311 | 445/18723 | 3.23e-04 | 3.42e-03 | 80 |
GO:00346559 | Cervix | CC | nucleobase-containing compound catabolic process | 74/2311 | 407/18723 | 3.77e-04 | 3.88e-03 | 74 |
GO:00434889 | Cervix | CC | regulation of mRNA stability | 35/2311 | 158/18723 | 3.80e-04 | 3.89e-03 | 35 |
GO:00434879 | Cervix | CC | regulation of RNA stability | 36/2311 | 170/18723 | 7.72e-04 | 6.86e-03 | 36 |
GO:00442709 | Cervix | CC | cellular nitrogen compound catabolic process | 79/2311 | 451/18723 | 7.80e-04 | 6.91e-03 | 79 |
GO:19023698 | Cervix | CC | negative regulation of RNA catabolic process | 19/2311 | 75/18723 | 1.54e-03 | 1.19e-02 | 19 |
GO:00194398 | Cervix | CC | aromatic compound catabolic process | 79/2311 | 467/18723 | 2.14e-03 | 1.54e-02 | 79 |
GO:19013618 | Cervix | CC | organic cyclic compound catabolic process | 80/2311 | 495/18723 | 6.77e-03 | 3.72e-02 | 80 |
GO:19023738 | Cervix | CC | negative regulation of mRNA catabolic process | 15/2311 | 63/18723 | 8.52e-03 | 4.40e-02 | 15 |
GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LARP4B | SNV | Missense_Mutation | novel | c.419N>C | p.Asn140Thr | p.N140T | Q92615 | protein_coding | tolerated(1) | benign(0.003) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
LARP4B | SNV | Missense_Mutation | novel | c.1616N>A | p.Gly539Glu | p.G539E | Q92615 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
LARP4B | SNV | Missense_Mutation | c.1393N>A | p.Gln465Lys | p.Q465K | Q92615 | protein_coding | tolerated(0.33) | benign(0.304) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
LARP4B | SNV | Missense_Mutation | novel | c.1895N>T | p.Ala632Val | p.A632V | Q92615 | protein_coding | tolerated(0.09) | possibly_damaging(0.511) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LARP4B | SNV | Missense_Mutation | novel | c.1105N>T | p.Ser369Cys | p.S369C | Q92615 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-DD-AAEI-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
LARP4B | SNV | Missense_Mutation | novel | c.1747G>A | p.Glu583Lys | p.E583K | Q92615 | protein_coding | deleterious(0.02) | benign(0.437) | TCGA-ZS-A9CE-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LARP4B | SNV | Missense_Mutation | c.1805N>T | p.Pro602Leu | p.P602L | Q92615 | protein_coding | deleterious(0.02) | benign(0.071) | TCGA-44-2656-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
LARP4B | SNV | Missense_Mutation | c.759N>C | p.Glu253Asp | p.E253D | Q92615 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-44-2661-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LARP4B | SNV | Missense_Mutation | rs113572102 | c.2159N>T | p.Ser720Leu | p.S720L | Q92615 | protein_coding | tolerated(0.08) | benign(0.031) | TCGA-44-A47A-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LARP4B | SNV | Missense_Mutation | novel | c.1012N>A | p.Ala338Thr | p.A338T | Q92615 | protein_coding | tolerated(0.62) | benign(0) | TCGA-49-6742-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | alimta | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |